NK1 receptor blockade disrupts microtumor growth and aggregation in a three-dimensional murine breast cancer model

Several data indicate that Substance P (SP) neurokinin type 1 receptor (NK1R) is at the center of the interaction between cancer cells and peripheral sensory neurons. Selecting the appropriate cancer cell line and its susceptibility to being modulated by NK1 antagonists are critical to studying this...

Full description

Saved in:
Bibliographic Details
Published inNeuropeptides (Edinburgh) Vol. 109; p. 102479
Main Authors Gutierrez, Silvia, Boada, M. Danilo
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 01.01.2025
Subjects
Online AccessGet full text
ISSN0143-4179
1532-2785
1532-2785
DOI10.1016/j.npep.2024.102479

Cover

Loading…
Abstract Several data indicate that Substance P (SP) neurokinin type 1 receptor (NK1R) is at the center of the interaction between cancer cells and peripheral sensory neurons. Selecting the appropriate cancer cell line and its susceptibility to being modulated by NK1 antagonists are critical to studying this complex interaction. In the current study, we have focused on this selection by comparing several aspects of the triple-negative breast cancer (TNBC) cell line (MDA-MB-231LUC+) with a modified murine cell line (E0771LUC+), both expressing luciferase. This comparison was made using several methods, SP stimulation and 3D cell culture models, to better reproduce the heterogenous microenvironment of solid tumors observed in vivo. Furthermore, the susceptibility of the murine cell line (E0771LUC+) to NK1R antagonist (Aprepitant) was tested. Our results indicate that E0771LUC+ recapitulates several essential aspects of the human cell line, rendering this murine line ideal to be used on immune-competent animals during in vivo studies. We have also found that both cell lines are susceptible to SP stimulation, and their proliferation is disrupted by NK1R antagonists (Aprepitant). In vivo studies are required to verify and refine these findings. [Display omitted] •SP and NK1R are key players driving the interaction between peripheral sensory neurons and cancer cells.•NK1R is present in both breast cancer cell lines.•SP induces breast cancer cell line proliferation, and an NK1R antagonist disrupts it.•Aprepitant alters E0771LUC+ 3D organization, causing size reduction and de-aggregation.
AbstractList Several data indicate that Substance P (SP) neurokinin type 1 receptor (NK1R) is at the center of the interaction between cancer cells and peripheral sensory neurons. Selecting the appropriate cancer cell line and its susceptibility to being modulated by NK1 antagonists are critical to studying this complex interaction. In the current study, we have focused on this selection by comparing several aspects of the triple-negative breast cancer (TNBC) cell line (MDA-MB-231LUC+) with a modified murine cell line (E0771LUC+), both expressing luciferase. This comparison was made using several methods, SP stimulation and 3D cell culture models, to better reproduce the heterogenous microenvironment of solid tumors observed in vivo. Furthermore, the susceptibility of the murine cell line (E0771LUC+) to NK1R antagonist (Aprepitant) was tested. Our results indicate that E0771LUC+ recapitulates several essential aspects of the human cell line, rendering this murine line ideal to be used on immune-competent animals during in vivo studies. We have also found that both cell lines are susceptible to SP stimulation, and their proliferation is disrupted by NK1R antagonists (Aprepitant). In vivo studies are required to verify and refine these findings. [Display omitted] •SP and NK1R are key players driving the interaction between peripheral sensory neurons and cancer cells.•NK1R is present in both breast cancer cell lines.•SP induces breast cancer cell line proliferation, and an NK1R antagonist disrupts it.•Aprepitant alters E0771LUC+ 3D organization, causing size reduction and de-aggregation.
Several data indicate that Substance P (SP) neurokinin type 1 receptor (NK1R) is at the center of the interaction between cancer cells and peripheral sensory neurons. Selecting the appropriate cancer cell line and its susceptibility to being modulated by NK1 antagonists are critical to studying this complex interaction. In the current study, we have focused on this selection by comparing several aspects of the triple-negative breast cancer (TNBC) cell line (MDA-MB-231LUC+) with a modified murine cell line (E0771LUC+), both expressing luciferase. This comparison was made using several methods, SP stimulation and 3D cell culture models, to better reproduce the heterogenous microenvironment of solid tumors observed in vivo. Furthermore, the susceptibility of the murine cell line (E0771LUC+) to NK1R antagonist (Aprepitant) was tested. Our results indicate that E0771LUC+ recapitulates several essential aspects of the human cell line, rendering this murine line ideal to be used on immune-competent animals during in vivo studies. We have also found that both cell lines are susceptible to SP stimulation, and their proliferation is disrupted by NK1R antagonists (Aprepitant). In vivo studies are required to verify and refine these findings.Several data indicate that Substance P (SP) neurokinin type 1 receptor (NK1R) is at the center of the interaction between cancer cells and peripheral sensory neurons. Selecting the appropriate cancer cell line and its susceptibility to being modulated by NK1 antagonists are critical to studying this complex interaction. In the current study, we have focused on this selection by comparing several aspects of the triple-negative breast cancer (TNBC) cell line (MDA-MB-231LUC+) with a modified murine cell line (E0771LUC+), both expressing luciferase. This comparison was made using several methods, SP stimulation and 3D cell culture models, to better reproduce the heterogenous microenvironment of solid tumors observed in vivo. Furthermore, the susceptibility of the murine cell line (E0771LUC+) to NK1R antagonist (Aprepitant) was tested. Our results indicate that E0771LUC+ recapitulates several essential aspects of the human cell line, rendering this murine line ideal to be used on immune-competent animals during in vivo studies. We have also found that both cell lines are susceptible to SP stimulation, and their proliferation is disrupted by NK1R antagonists (Aprepitant). In vivo studies are required to verify and refine these findings.
Several data indicate that Substance P (SP) neurokinin type 1 receptor (NK1R) is at the center of the interaction between cancer cells and peripheral sensory neurons. Selecting the appropriate cancer cell line and its susceptibility to being modulated by NK1 antagonists are critical to studying this complex interaction. In the current study, we have focused on this selection by comparing several aspects of the triple-negative breast cancer (TNBC) cell line (MDA-MB-231 ) with a modified murine cell line (E0771 ), both expressing luciferase. This comparison was made using several methods, SP stimulation and 3D cell culture models, to better reproduce the heterogenous microenvironment of solid tumors observed in vivo. Furthermore, the susceptibility of the murine cell line (E0771 ) to NK1R antagonist (Aprepitant) was tested. Our results indicate that E0771 recapitulates several essential aspects of the human cell line, rendering this murine line ideal to be used on immune-competent animals during in vivo studies. We have also found that both cell lines are susceptible to SP stimulation, and their proliferation is disrupted by NK1R antagonists (Aprepitant). In vivo studies are required to verify and refine these findings.
ArticleNumber 102479
Author Boada, M. Danilo
Gutierrez, Silvia
Author_xml – sequence: 1
  givenname: Silvia
  surname: Gutierrez
  fullname: Gutierrez, Silvia
  email: sgutierr@wakehealth.edu
– sequence: 2
  givenname: M. Danilo
  surname: Boada
  fullname: Boada, M. Danilo
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39591909$$D View this record in MEDLINE/PubMed
BookMark eNqFkU1v1DAQhi1URLeFP8AB-cglyzh24hhxQRVfooILnC3Hnt16m9jBdqj67_FqCwcOcLI08zyW5n0vyFmIAQl5zmDLgPWvDtuw4LJtoRV10AqpHpEN63jbtHLozsgGmOCNYFKdk4ucDwAg2mF4Qs656hRToDYkffnMaEKLS4mJjlO0t8YhdT6ndSmZzt6mWNa5Lvcp3pUbaoKjZr9PuDfFx0B9oIaWm4TYOD9jyHVoJjqvyQekY0KTC7UmWEx0jg6np-TxzkwZnz28l-T7-3ffrj42118_fLp6e91Y3g2l6eXIFUoldiBZ77gdHXDccTC9cnbgBpjsAHgvmYOuExLrFqWptygD3cgvycvTv0uKP1bMRc8-W5wmEzCuWXPGuWCiA1XRFw_oOs7o9JL8bNK9_p1TBdoTUNPIOeHuD8JAH8vQB30sQx_L0KcyqvTmJGG98qfHpLP1WINwviZetIv-3_rrv3Q7-eCtmW7x_n_yL35Kptk
Cites_doi 10.1016/j.biopha.2018.09.013
10.1016/j.pain.2011.02.009
10.1038/s41467-018-03889-3
10.1111/j.1749-6632.1990.tb40470.x
10.1186/s12935-018-0707-8
10.1523/JNEUROSCI.15-11-07633.1995
10.1371/journal.pone.0123312
10.1111/bph.12589
10.14440/jbm.2016.132
10.2174/092986710790416308
10.1158/0008-5472.CAN-15-2304
10.1002/ijc.32270
10.3390/cancers13153871
10.1083/jcb.125.2.403
10.1007/s11033-019-04599-9
10.1091/mbc.E22-02-0055
10.1007/s10549-013-2599-6
10.1177/17448069211024082
10.3390/cancers13112703
10.1016/j.jpain.2014.07.003
10.1186/s12864-019-6344-3
10.3390/cancers14143539
10.18632/oncotarget.15695
10.1186/s12955-016-0449-z
10.3390/cancers12092682
10.1177/00220345221088527
10.1097/j.pain.0000000000001986
10.1074/jbc.REV119.007759
10.1186/s12935-020-01418-1
10.3892/ijo.2014.2565
10.3390/ijms23158479
10.3748/wjg.v20.i9.2321
10.3389/fchem.2020.00571
10.1155/2015/495704
10.1152/physrev.00031.2013
10.1007/s00441-018-2922-y
10.1124/jpet.110.175976
10.1158/0008-5472.CAN-14-3180
10.1097/00001813-200511000-00007
10.1038/s41586-024-07767-5
10.1177/1744806919845750
ContentType Journal Article
Copyright 2024 The Authors
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
Copyright_xml – notice: 2024 The Authors
– notice: Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
DBID 6I.
AAFTH
AAYXX
CITATION
NPM
7X8
DOI 10.1016/j.npep.2024.102479
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Chemistry
EISSN 1532-2785
ExternalDocumentID 39591909
10_1016_j_npep_2024_102479
S0143417924000787
Genre Journal Article
GroupedDBID ---
--K
--M
.1-
.FO
.GJ
.~1
0R~
123
1B1
1P~
1RT
1~.
1~5
4.4
457
4G.
53G
5RE
5VS
7-5
71M
8P~
9JM
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAXKI
AAXLA
AAXUO
AAYWO
ABBQC
ABCQJ
ABFRF
ABGSF
ABIVO
ABJNI
ABMAC
ABMZM
ABUDA
ABWVN
ABXDB
ACDAQ
ACGFO
ACGFS
ACIEU
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
ADUVX
AEBSH
AEFWE
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFFNX
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGRDE
AGUBO
AGWIK
AGYEJ
AHHHB
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRLJ
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CAG
COF
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HDW
HMK
HMO
HVGLF
HZ~
IHE
J1W
KOM
LX8
M29
M41
MO0
MOBAO
N9A
O-L
O9-
OAUVE
OB0
ON-
OZT
P-8
P-9
P2P
PC.
Q38
R2-
ROL
RPZ
SAE
SDF
SDG
SEL
SES
SEW
SPCBC
SSH
SSN
SSZ
T5K
UHS
UNMZH
WUQ
Z5R
ZGI
~G-
6I.
AACTN
AAFTH
AEHWI
AFCTW
AFKWA
AJOXV
AMFUW
RIG
SSU
AAYXX
AGRNS
CITATION
NPM
7X8
ID FETCH-LOGICAL-c358t-67b39e794f0716d3cbd03ef30a69dc83a0175003671d05547e3efe7aece9a05b3
IEDL.DBID .~1
ISSN 0143-4179
1532-2785
IngestDate Fri Jul 11 01:27:07 EDT 2025
Wed Feb 19 02:03:04 EST 2025
Tue Jul 01 01:07:38 EDT 2025
Sat Jan 11 15:48:43 EST 2025
Tue Aug 26 18:36:35 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords Aprepitant
Neuropeptides
NK1R
Breast cancer
Substance P
Microtumors
Language English
License This is an open access article under the CC BY-NC-ND license.
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c358t-67b39e794f0716d3cbd03ef30a69dc83a0175003671d05547e3efe7aece9a05b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.sciencedirect.com/science/article/pii/S0143417924000787
PMID 39591909
PQID 3133414509
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3133414509
pubmed_primary_39591909
crossref_primary_10_1016_j_npep_2024_102479
elsevier_sciencedirect_doi_10_1016_j_npep_2024_102479
elsevier_clinicalkey_doi_10_1016_j_npep_2024_102479
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate January 2025
2025-01-00
2025-Jan
20250101
PublicationDateYYYYMMDD 2025-01-01
PublicationDate_xml – month: 01
  year: 2025
  text: January 2025
PublicationDecade 2020
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Neuropeptides (Edinburgh)
PublicationTitleAlternate Neuropeptides
PublicationYear 2025
Publisher Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
References Beirith, Renz, Mudusetti, Ring, Kolorz, Koch, Bazhin, Berger, Wang, Angele, D’Haese, Guba, Niess, Andrassy, Werner, Ilmer (bb0025) 2021 May 30; 13
Janiszewska, Primi, Izard (bb0090) 2020 Feb 21; 295
Muñoz, Coveñas (bb0120) 2014 Mar 7; 20
Si, Zhao, Pedroza, Zaske, Rosen, Creighton, Roarty (bb0185) 2022 Sep 15; 33
Zhou, Zhao, Xiong, Chen, Zhang, Yu, Yang, Yao (bb0250) 2013 Jul; 140
Tatsushima, Egashira, Kawashiri, Mihara, Yano, Mishima, Oishi (bb0210) 2011 Apr; 337
Jobling, Pundavela, Oliveira, Roselli, Walker, Hondermarck (bb0095) 2015 May 1; 75
Gutierrez, Eisenach, Boada (bb0080) 2021 Jan–Dec; 17
Nief, Gonzales, Chelales, Agudogo, Crouch, Nair, Ramanujam (bb0150) 2022 Jul 30; 23
Szlachcic, Switonski, Krzyzosiak, Figlerowicz, Figiel (bb0205) 2015 Sep; 8
Gutierrez, Boada (bb0070) 2018 Dec 22; 18
Steinhoff, von Mentzer, Geppetti, Pothoulakis, Bunnett (bb0200) 2014 Jan; 94
Le Naour, Koffi, Diab, Le Guennec, Rougé, Aldekwer, Goncalves-Mendes, Talvas, Farges, Caldefie-Chezet, Vasson, Rossary (bb0105) 2020 Jul 20; 20
Zieglgänsberger (bb0255) 2019 Jan; 375
Benton, DeGray, Kleinman, George, Arnaoutova (bb0030) 2015 Apr 9; 10
Singh, Mukundan, Jaramillo, Oesterreich, Sant (bb0190) 2016 Jul 1; 76
Afsharimani, Doornebal, Cabot, Hollmann, Parat (bb0005) 2015 Jan; 172
Pulaski, Ostrand-Rosenberg (bb0170) 2001 May
Luo, Li, Wang, Yang, Yuan, Wang, Cherasse, Lazarus, Chen, Qu, Huang (bb0110) 2018 Apr 20; 9
Muñoz, Coveñas (bb0125) 2016 Jul–Aug; 22
Coveñas, Muñoz (bb0050) 2022 Jul 21; 14
Dwyer, Ellies, Holme, Pixley (bb0060) 2016 Jul 24; 3
Garcia-Recio, Gascón (bb0065) 2015; 2015
Yang, Yang, Hu, Watson, Liu, Geiger, Anver, Haines, Martin, Green, Lee, Hunter, Wakefield (bb0235) 2017 May 9; 8
Arroyo-Crespo, Armiñán, Charbonnier, Deladriere, Palomino-Schätzlein, Lamas-Domingo, Forteza, Pineda-Lucena, Vicent (bb0010) 2019 Oct 15; 145
Noguchi, Kawai, Fukuoka, Senba, Miki (bb0160) 1995 Nov; 15
Davoodian, Boroumand, Mehrabi Bahar, Jafarian, Asadi, Hashemy (bb0055) 2019 Feb; 46
Chen, Zhang, Zhou, Zhu, Sun, Feng (bb0040) 2019 Jan 1; 9
Bigioni, Benzo, Irrissuto, Maggi, Goso (bb0035) 2005 Nov; 16
Gutierrez, Alvarado-Vázquez, Eisenach, Romero-Sandoval, Boada (bb0075) 2019 Jan–Dec; 15
van de Ven, Tenhagen, Meuleman, van Riel, Schackmann, Derksen (bb0225) 2015 Apr; 8
Padmanaban, Keller, Seltzer, Ostendorf, Kerner, Tavazoie (bb0165) 2024 Sep; 633
Lam, Schmidt (bb0100) 2011 May; 152
Ye, Jensen, Viet, Pan, Campana, Amit, Boada (bb0240) 2022 Aug; 101
Hoppenz, Els-Heindl, Beck-Sickinger (bb0085) 2020 Jul 7
Aslakson, Miller (bb0015) 1992 Mar 15; 52
Bates, Buret, van Helden, Horton, Burns (bb0020) 1994 Apr; 125
Salvo, Campana, Scheff, Nguyen, Jeong, Wall, Wu, Zhang, Kim, Bhattacharya, Janal, Liu, Albertson, Schmidt, Dolan, Schmidt, Boada, Ye (bib257) 2020; 161
Zhong, Myers, Wang, Wang, Lucas, Rosfjord, Lucas, Hooper, Yang, Lemon, Guffroy, May, Bienkowska, Rejto (bb0245) 2020 Jan 2; 21
Cipriano, Mesquita (bb0045) 2021 Mar 22; 15
Muñoz, Crespo, Crespo, Coveñas (bb0145) 2019 Jul; 11
U.S. Food and Drug Administration (bb0220) November 5, 2002
Muñoz, Coveñas (bb0130) 2020 Sep 20; 12
Nizam, Erin (bb0155) 2018 Dec; 108
McGillis, Mitsuhashi, Payan (bb0115) 1990; 594
Reyes-Gibby, Anderson, Merriman, Todd, Shete, Hanna (bb0175) 2014 Oct; 15
The Breast Cancer Landscape (bb0215) October 2021
Velasco-Ortega, Monsalve-Guil, Jiménez-Guerra, Ortiz-García, Crespo De La Rosa, Coveñas, Muñoz (bb0230) 2020 Jan–Feb; 34
Muñoz, Rosso, Coveñas (bb0135) 2010; 17
Rodriguez, Pei, Kim, German, Robinson (bb0180) 2021 Jul 31; 13
Smyth, Shen, Bowman, Peterson, John, Melemed, Liepa (bb0195) 2016 Mar 25
Muñoz, González-Ortega, Salinas-Martín, Carranza, Garcia-Recio, Almendro, Coveñas (bb0140) 2014 Oct; 45
Tatsushima (10.1016/j.npep.2024.102479_bb0210) 2011; 337
Zhong (10.1016/j.npep.2024.102479_bb0245) 2020; 21
Muñoz (10.1016/j.npep.2024.102479_bb0140) 2014; 45
Si (10.1016/j.npep.2024.102479_bb0185) 2022; 33
Muñoz (10.1016/j.npep.2024.102479_bb0135) 2010; 17
Gutierrez (10.1016/j.npep.2024.102479_bb0075) 2019; 15
van de Ven (10.1016/j.npep.2024.102479_bb0225) 2015; 8
Singh (10.1016/j.npep.2024.102479_bb0190) 2016; 76
Ye (10.1016/j.npep.2024.102479_bb0240) 2022; 101
Zhou (10.1016/j.npep.2024.102479_bb0250) 2013; 140
Pulaski (10.1016/j.npep.2024.102479_bb0170) 2001
Muñoz (10.1016/j.npep.2024.102479_bb0125) 2016; 22
Reyes-Gibby (10.1016/j.npep.2024.102479_bb0175) 2014; 15
Lam (10.1016/j.npep.2024.102479_bb0100) 2011; 152
Nief (10.1016/j.npep.2024.102479_bb0150) 2022; 23
Padmanaban (10.1016/j.npep.2024.102479_bb0165) 2024; 633
Szlachcic (10.1016/j.npep.2024.102479_bb0205) 2015; 8
Dwyer (10.1016/j.npep.2024.102479_bb0060) 2016; 3
Steinhoff (10.1016/j.npep.2024.102479_bb0200) 2014; 94
Smyth (10.1016/j.npep.2024.102479_bb0195) 2016
Nizam (10.1016/j.npep.2024.102479_bb0155) 2018; 108
Salvo (10.1016/j.npep.2024.102479_bib257) 2020; 161
Luo (10.1016/j.npep.2024.102479_bb0110) 2018; 9
Coveñas (10.1016/j.npep.2024.102479_bb0050) 2022; 14
Davoodian (10.1016/j.npep.2024.102479_bb0055) 2019; 46
Benton (10.1016/j.npep.2024.102479_bb0030) 2015; 10
Gutierrez (10.1016/j.npep.2024.102479_bb0080) 2021; 17
Janiszewska (10.1016/j.npep.2024.102479_bb0090) 2020; 295
Le Naour (10.1016/j.npep.2024.102479_bb0105) 2020; 20
Chen (10.1016/j.npep.2024.102479_bb0040) 2019; 9
Velasco-Ortega (10.1016/j.npep.2024.102479_bb0230) 2020; 34
Afsharimani (10.1016/j.npep.2024.102479_bb0005) 2015; 172
Beirith (10.1016/j.npep.2024.102479_bb0025) 2021; 13
Garcia-Recio (10.1016/j.npep.2024.102479_bb0065) 2015; 2015
Arroyo-Crespo (10.1016/j.npep.2024.102479_bb0010) 2019; 145
Muñoz (10.1016/j.npep.2024.102479_bb0120) 2014; 20
The Breast Cancer Landscape (10.1016/j.npep.2024.102479_bb0215)
Zieglgänsberger (10.1016/j.npep.2024.102479_bb0255) 2019; 375
Hoppenz (10.1016/j.npep.2024.102479_bb0085) 2020
Jobling (10.1016/j.npep.2024.102479_bb0095) 2015; 75
Aslakson (10.1016/j.npep.2024.102479_bb0015) 1992; 52
Bigioni (10.1016/j.npep.2024.102479_bb0035) 2005; 16
Noguchi (10.1016/j.npep.2024.102479_bb0160) 1995; 15
Yang (10.1016/j.npep.2024.102479_bb0235) 2017; 8
McGillis (10.1016/j.npep.2024.102479_bb0115) 1990; 594
Gutierrez (10.1016/j.npep.2024.102479_bb0070) 2018; 18
Bates (10.1016/j.npep.2024.102479_bb0020) 1994; 125
Rodriguez (10.1016/j.npep.2024.102479_bb0180) 2021; 13
Cipriano (10.1016/j.npep.2024.102479_bb0045) 2021; 15
Muñoz (10.1016/j.npep.2024.102479_bb0130) 2020; 12
Muñoz (10.1016/j.npep.2024.102479_bb0145) 2019; 11
U.S. Food and Drug Administration (10.1016/j.npep.2024.102479_bb0220)
References_xml – volume: 8
  start-page: 373
  year: 2015 Apr
  end-page: 384
  ident: bb0225
  article-title: Nuclear p120-catenin regulates the anoikis resistance of mouse lobular breast cancer cells through Kaiso-dependent Wnt11 expression
  publication-title: Dis. Model. Mech.
– volume: 161
  start-page: 2592
  year: 2020
  end-page: 2602
  ident: bib257
  article-title: Peripheral nerve injury and sensitization underlie pain associated with oral cancer perineural invasion
  publication-title: Pain
– volume: 15
  start-page: 1015
  year: 2014 Oct
  end-page: 1022
  ident: bb0175
  article-title: Survival patterns in squamous cell carcinoma of the head and neck: pain as an independent prognostic factor for survival
  publication-title: J. Pain
– volume: 11
  start-page: 50
  year: 2019 Jul
  end-page: 54
  ident: bb0145
  article-title: Neurokinin-1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: a case report
  publication-title: Mol. Clin. Oncol.
– volume: 13
  start-page: 2703
  year: 2021 May 30
  ident: bb0025
  article-title: Identification of the neurokinin-1 receptor as targetable stratification factor for drug repurposing in pancreatic cancer
  publication-title: Cancers (Basel)
– volume: 16
  start-page: 1083
  year: 2005 Nov
  end-page: 1089
  ident: bb0035
  article-title: Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231
  publication-title: Anti-Cancer Drugs
– volume: 94
  start-page: 265
  year: 2014 Jan
  end-page: 301
  ident: bb0200
  article-title: Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease
  publication-title: Physiol. Rev.
– volume: 18
  start-page: 216
  year: 2018 Dec 22
  ident: bb0070
  article-title: Neuropeptide-induced modulation of carcinogenesis in a metastatic breast cancer cell line (MDA-MB-231LUC+)
  publication-title: Cancer Cell Int.
– volume: 13
  start-page: 3871
  year: 2021 Jul 31
  ident: bb0180
  article-title: Substance P antagonism as a novel therapeutic option to enhance efficacy of cisplatin in triple negative breast cancer and protect PC12 cells against cisplatin-induced oxidative stress and apoptosis
  publication-title: Cancers (Basel)
– volume: 145
  start-page: 2267
  year: 2019 Oct 15
  end-page: 2281
  ident: bb0010
  article-title: Characterization of triple-negative breast cancer preclinical models provides functional evidence of metastatic progression
  publication-title: Int. J. Cancer
– volume: 14
  start-page: 3539
  year: 2022 Jul 21
  ident: bb0050
  article-title: Involvement of the substance P/neurokinin-1 receptor system in cancer
  publication-title: Cancers (Basel)
– volume: 52
  start-page: 1399
  year: 1992 Mar 15
  end-page: 1405
  ident: bb0015
  article-title: Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor
  publication-title: Cancer Res.
– volume: 45
  start-page: 1658
  year: 2014 Oct
  end-page: 1672
  ident: bb0140
  article-title: The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer
  publication-title: Int. J. Oncol.
– volume: 108
  start-page: 263
  year: 2018 Dec
  end-page: 270
  ident: bb0155
  article-title: Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; effects independent of substance P
  publication-title: Biomed. Pharmacother.
– volume: 17
  year: 2021 Jan–Dec
  ident: bb0080
  article-title: Seeding of breast cancer cell line (MDA-MB-231LUC+) to the mandible induces overexpression of substance P and CGRP throughout the trigeminal ganglion and widespread peripheral sensory neuropathy throughout all three of its divisions
  publication-title: Mol. Pain
– start-page: 571
  year: 2020 Jul 7
  ident: bb0085
  article-title: Peptide-drug conjugates and their targets in advanced cancer therapies
  publication-title: Front. Chem.
– year: November 5, 2002
  ident: bb0220
  article-title: Center for Drug Evaluation and Research. Emend NDA 21–549 approval letter
– volume: 9
  start-page: 1576
  year: 2018 Apr 20
  ident: bb0110
  article-title: Nucleus accumbens controls wakefulness by a subpopulation of neurons expressing dopamine D1 receptors
  publication-title: Nat. Commun.
– volume: 337
  start-page: 226
  year: 2011 Apr
  end-page: 235
  ident: bb0210
  article-title: Involvement of substance P in peripheral neuropathy induced by paclitaxel but not oxaliplatin
  publication-title: J. Pharmacol. Exp. Ther.
– volume: 375
  start-page: 227
  year: 2019 Jan
  end-page: 241
  ident: bb0255
  article-title: Substance P and pain chronicity
  publication-title: Cell Tissue Res.
– volume: 594
  start-page: 85
  year: 1990
  end-page: 94
  ident: bb0115
  article-title: Immunomodulation by tachykinin neuropeptides
  publication-title: Ann. N. Y. Acad. Sci.
– volume: 12
  start-page: 2682
  year: 2020 Sep 20
  ident: bb0130
  article-title: The neurokinin-1 receptor antagonist aprepitant: an intelligent bullet against cancer?
  publication-title: Cancers (Basel)
– volume: 46
  start-page: 1285
  year: 2019 Feb
  end-page: 1293
  ident: bb0055
  article-title: Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in breast cancer
  publication-title: Mol. Biol. Rep.
– volume: 21
  start-page: 2
  year: 2020 Jan 2
  ident: bb0245
  article-title: Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors
  publication-title: BMC Genomics
– volume: 15
  start-page: 7633
  year: 1995 Nov
  end-page: 7643
  ident: bb0160
  article-title: Substance P induced by peripheral nerve injury in primary afferent sensory neurons and its effect on dorsal column nucleus neurons
  publication-title: J. Neurosci.
– volume: 15
  year: 2021 Mar 22
  ident: bb0045
  article-title: Emerging therapeutic drugs in metastatic triple-negative breast cancer
  publication-title: Breast Cancer (Auckl.)
– volume: 23
  start-page: 8479
  year: 2022 Jul 30
  ident: bb0150
  article-title: Targeting tumor acidosis and regulatory T cells unmasks anti-metastatic potential of local tumor ablation in triple-negative breast cancer
  publication-title: Int. J. Mol. Sci.
– start-page: 52
  year: 2016 Mar 25
  ident: bb0195
  article-title: Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer
  publication-title: Health Qual. Life Outcomes
– volume: 75
  start-page: 1777
  year: 2015 May 1
  end-page: 1781
  ident: bb0095
  article-title: Nerve-cancer cell cross-talk: a novel promoter of tumor progression
  publication-title: Cancer Res.
– volume: 633
  start-page: 207
  year: 2024 Sep
  end-page: 215
  ident: bb0165
  article-title: Neuronal substance P drives metastasis through an extracellular RNA-TLR7 axis
  publication-title: Nature
– volume: 2015
  year: 2015
  ident: bb0065
  article-title: Biological and pharmacological aspects of the NK1-receptor
  publication-title: Biomed. Res. Int.
– volume: 20
  start-page: 328
  year: 2020 Jul 20
  ident: bb0105
  article-title: EO771, the first luminal B mammary cancer cell line from C57BL/6 mice
  publication-title: Cancer Cell Int.
– volume: 9
  start-page: 1
  year: 2019 Jan 1
  end-page: 21
  ident: bb0040
  article-title: Perineural invasion of cancer: a complex crosstalk between cells and molecules in the perineural niche
  publication-title: Am. J. Cancer Res.
– volume: 172
  start-page: 251
  year: 2015 Jan
  end-page: 259
  ident: bb0005
  article-title: Comparison and analysis of the animal models used to study the effect of morphine on tumour growth and metastasis
  publication-title: Br. J. Pharmacol.
– volume: 20
  start-page: 2321
  year: 2014 Mar 7
  end-page: 2334
  ident: bb0120
  article-title: Involvement of substance P and the NK-1 receptor in pancreatic cancer
  publication-title: World J. Gastroenterol.
– volume: 152
  start-page: 1206
  year: 2011 May
  end-page: 1209
  ident: bb0100
  article-title: Orofacial pain onset predicts transition to head and neck cancer
  publication-title: Pain
– volume: 8
  start-page: 30621
  year: 2017 May 9
  end-page: 30643
  ident: bb0235
  article-title: Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis
  publication-title: Oncotarget
– volume: 140
  start-page: 49
  year: 2013 Jul
  end-page: 61
  ident: bb0250
  article-title: Roles of full-length and truncated neurokinin-1 receptors on tumor progression and distant metastasis in human breast cancer
  publication-title: Breast Cancer Res. Treat.
– volume: 34
  start-page: 215
  year: 2020 Jan–Feb
  end-page: 219
  ident: bb0230
  article-title: Involvement of the substance P/neurokinin-1 receptor system in oral pain and inflammation
  publication-title: J. Biol. Regul. Homeost. Agents
– volume: 295
  start-page: 2495
  year: 2020 Feb 21
  end-page: 2505
  ident: bb0090
  article-title: Cell adhesion in cancer: beyond the migration of single cells
  publication-title: J. Biol. Chem.
– volume: 33
  start-page: ar103
  year: 2022 Sep 15
  ident: bb0185
  article-title: Noncanonical Wnt/Ror2 signaling regulates cell-matrix adhesion to prompt directional tumor cell invasion in breast cancer
  publication-title: Mol. Biol. Cell
– volume: 76
  start-page: 3732
  year: 2016 Jul 1
  end-page: 3743
  ident: bb0190
  article-title: Three-dimensional breast cancer models mimic hallmarks of size-induced tumor progression
  publication-title: Cancer Res.
– volume: 17
  start-page: 504
  year: 2010
  end-page: 516
  ident: bb0135
  article-title: A new frontier in the treatment of cancer: NK-1 receptor antagonists
  publication-title: Curr. Med. Chem.
– volume: 125
  start-page: 403
  year: 1994 Apr
  end-page: 415
  ident: bb0020
  article-title: Apoptosis induced by inhibition of intercellular contact
  publication-title: J. Cell Biol.
– volume: 3
  year: 2016 Jul 24
  ident: bb0060
  article-title: A three-dimensional co-culture system to investigate macrophage-dependent tumor cell invasion
  publication-title: J. Biol. Methods
– year: 2001 May
  ident: bb0170
  article-title: Mouse 4T1 breast tumor model
  publication-title: Curr Protoc Immunol
– volume: 101
  start-page: 1025
  year: 2022 Aug
  end-page: 1033
  ident: bb0240
  article-title: Advances in head and neck cancer pain
  publication-title: J. Dent. Res.
– volume: 8
  start-page: 1047
  year: 2015 Sep
  end-page: 1057
  ident: bb0205
  article-title: Huntington disease iPSCs show early molecular changes in intracellular signaling, the expression of oxidative stress proteins and the p53 pathway
  publication-title: Dis. Model. Mech.
– year: October 2021
  ident: bb0215
  article-title: Department of Defense Breast Cancer Research Program
– volume: 22
  start-page: 260
  year: 2016 Jul–Aug
  end-page: 268
  ident: bb0125
  article-title: Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: a new approach. Saudi
  publication-title: J. Gastroenterol.
– volume: 15
  year: 2019 Jan–Dec
  ident: bb0075
  article-title: Tachykinins modulate nociceptive responsiveness and sensitization: in vivo electrical characterization of primary sensory neurons in tachykinin knockout (Tac1 KO) mice
  publication-title: Mol. Pain
– volume: 10
  year: 2015 Apr 9
  ident: bb0030
  article-title: In vitro microtumors provide a physiologically predictive tool for breast cancer therapeutic screening
  publication-title: PLoS One
– volume: 108
  start-page: 263
  year: 2018
  ident: 10.1016/j.npep.2024.102479_bb0155
  article-title: Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; effects independent of substance P
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2018.09.013
– volume: 152
  start-page: 1206
  issue: 5
  year: 2011
  ident: 10.1016/j.npep.2024.102479_bb0100
  article-title: Orofacial pain onset predicts transition to head and neck cancer
  publication-title: Pain
  doi: 10.1016/j.pain.2011.02.009
– volume: 52
  start-page: 1399
  issue: 6
  year: 1992
  ident: 10.1016/j.npep.2024.102479_bb0015
  article-title: Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor
  publication-title: Cancer Res.
– volume: 9
  start-page: 1576
  issue: 1
  year: 2018
  ident: 10.1016/j.npep.2024.102479_bb0110
  article-title: Nucleus accumbens controls wakefulness by a subpopulation of neurons expressing dopamine D1 receptors
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-03889-3
– volume: 594
  start-page: 85
  year: 1990
  ident: 10.1016/j.npep.2024.102479_bb0115
  article-title: Immunomodulation by tachykinin neuropeptides
  publication-title: Ann. N. Y. Acad. Sci.
  doi: 10.1111/j.1749-6632.1990.tb40470.x
– volume: 18
  start-page: 216
  year: 2018
  ident: 10.1016/j.npep.2024.102479_bb0070
  article-title: Neuropeptide-induced modulation of carcinogenesis in a metastatic breast cancer cell line (MDA-MB-231LUC+)
  publication-title: Cancer Cell Int.
  doi: 10.1186/s12935-018-0707-8
– volume: 15
  start-page: 7633
  issue: 11
  year: 1995
  ident: 10.1016/j.npep.2024.102479_bb0160
  article-title: Substance P induced by peripheral nerve injury in primary afferent sensory neurons and its effect on dorsal column nucleus neurons
  publication-title: J. Neurosci.
  doi: 10.1523/JNEUROSCI.15-11-07633.1995
– volume: 8
  start-page: 1047
  issue: 9
  year: 2015
  ident: 10.1016/j.npep.2024.102479_bb0205
  article-title: Huntington disease iPSCs show early molecular changes in intracellular signaling, the expression of oxidative stress proteins and the p53 pathway
  publication-title: Dis. Model. Mech.
– volume: 10
  issue: 4
  year: 2015
  ident: 10.1016/j.npep.2024.102479_bb0030
  article-title: In vitro microtumors provide a physiologically predictive tool for breast cancer therapeutic screening
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0123312
– volume: 172
  start-page: 251
  issue: 2
  year: 2015
  ident: 10.1016/j.npep.2024.102479_bb0005
  article-title: Comparison and analysis of the animal models used to study the effect of morphine on tumour growth and metastasis
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/bph.12589
– volume: 3
  issue: 3
  year: 2016
  ident: 10.1016/j.npep.2024.102479_bb0060
  article-title: A three-dimensional co-culture system to investigate macrophage-dependent tumor cell invasion
  publication-title: J. Biol. Methods
  doi: 10.14440/jbm.2016.132
– ident: 10.1016/j.npep.2024.102479_bb0220
– year: 2001
  ident: 10.1016/j.npep.2024.102479_bb0170
  article-title: Mouse 4T1 breast tumor model
– volume: 17
  start-page: 504
  issue: 6
  year: 2010
  ident: 10.1016/j.npep.2024.102479_bb0135
  article-title: A new frontier in the treatment of cancer: NK-1 receptor antagonists
  publication-title: Curr. Med. Chem.
  doi: 10.2174/092986710790416308
– volume: 76
  start-page: 3732
  issue: 13
  year: 2016
  ident: 10.1016/j.npep.2024.102479_bb0190
  article-title: Three-dimensional breast cancer models mimic hallmarks of size-induced tumor progression
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-15-2304
– volume: 145
  start-page: 2267
  issue: 8
  year: 2019
  ident: 10.1016/j.npep.2024.102479_bb0010
  article-title: Characterization of triple-negative breast cancer preclinical models provides functional evidence of metastatic progression
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.32270
– volume: 13
  start-page: 3871
  issue: 15
  year: 2021
  ident: 10.1016/j.npep.2024.102479_bb0180
  article-title: Substance P antagonism as a novel therapeutic option to enhance efficacy of cisplatin in triple negative breast cancer and protect PC12 cells against cisplatin-induced oxidative stress and apoptosis
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers13153871
– volume: 125
  start-page: 403
  issue: 2
  year: 1994
  ident: 10.1016/j.npep.2024.102479_bb0020
  article-title: Apoptosis induced by inhibition of intercellular contact
  publication-title: J. Cell Biol.
  doi: 10.1083/jcb.125.2.403
– volume: 46
  start-page: 1285
  issue: 1
  year: 2019
  ident: 10.1016/j.npep.2024.102479_bb0055
  article-title: Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in breast cancer
  publication-title: Mol. Biol. Rep.
  doi: 10.1007/s11033-019-04599-9
– volume: 33
  start-page: ar103
  issue: 11
  year: 2022
  ident: 10.1016/j.npep.2024.102479_bb0185
  article-title: Noncanonical Wnt/Ror2 signaling regulates cell-matrix adhesion to prompt directional tumor cell invasion in breast cancer
  publication-title: Mol. Biol. Cell
  doi: 10.1091/mbc.E22-02-0055
– volume: 140
  start-page: 49
  issue: 1
  year: 2013
  ident: 10.1016/j.npep.2024.102479_bb0250
  article-title: Roles of full-length and truncated neurokinin-1 receptors on tumor progression and distant metastasis in human breast cancer
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-013-2599-6
– volume: 17
  year: 2021
  ident: 10.1016/j.npep.2024.102479_bb0080
  article-title: Seeding of breast cancer cell line (MDA-MB-231LUC+) to the mandible induces overexpression of substance P and CGRP throughout the trigeminal ganglion and widespread peripheral sensory neuropathy throughout all three of its divisions
  publication-title: Mol. Pain
  doi: 10.1177/17448069211024082
– volume: 13
  start-page: 2703
  issue: 11
  year: 2021
  ident: 10.1016/j.npep.2024.102479_bb0025
  article-title: Identification of the neurokinin-1 receptor as targetable stratification factor for drug repurposing in pancreatic cancer
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers13112703
– volume: 15
  start-page: 1015
  issue: 10
  year: 2014
  ident: 10.1016/j.npep.2024.102479_bb0175
  article-title: Survival patterns in squamous cell carcinoma of the head and neck: pain as an independent prognostic factor for survival
  publication-title: J. Pain
  doi: 10.1016/j.jpain.2014.07.003
– volume: 21
  start-page: 2
  issue: 1
  year: 2020
  ident: 10.1016/j.npep.2024.102479_bb0245
  article-title: Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors
  publication-title: BMC Genomics
  doi: 10.1186/s12864-019-6344-3
– volume: 14
  start-page: 3539
  issue: 14
  year: 2022
  ident: 10.1016/j.npep.2024.102479_bb0050
  article-title: Involvement of the substance P/neurokinin-1 receptor system in cancer
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers14143539
– volume: 15
  year: 2021
  ident: 10.1016/j.npep.2024.102479_bb0045
  article-title: Emerging therapeutic drugs in metastatic triple-negative breast cancer
  publication-title: Breast Cancer (Auckl.)
– volume: 22
  start-page: 260
  issue: 4
  year: 2016
  ident: 10.1016/j.npep.2024.102479_bb0125
  article-title: Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: a new approach. Saudi
  publication-title: J. Gastroenterol.
– volume: 8
  start-page: 30621
  issue: 19
  year: 2017
  ident: 10.1016/j.npep.2024.102479_bb0235
  article-title: Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.15695
– start-page: 52
  issue: 14
  year: 2016
  ident: 10.1016/j.npep.2024.102479_bb0195
  article-title: Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer
  publication-title: Health Qual. Life Outcomes
  doi: 10.1186/s12955-016-0449-z
– volume: 12
  start-page: 2682
  issue: 9
  year: 2020
  ident: 10.1016/j.npep.2024.102479_bb0130
  article-title: The neurokinin-1 receptor antagonist aprepitant: an intelligent bullet against cancer?
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers12092682
– volume: 101
  start-page: 1025
  issue: 9
  year: 2022
  ident: 10.1016/j.npep.2024.102479_bb0240
  article-title: Advances in head and neck cancer pain
  publication-title: J. Dent. Res.
  doi: 10.1177/00220345221088527
– ident: 10.1016/j.npep.2024.102479_bb0215
– volume: 161
  start-page: 2592
  issue: 11
  year: 2020
  ident: 10.1016/j.npep.2024.102479_bib257
  article-title: Peripheral nerve injury and sensitization underlie pain associated with oral cancer perineural invasion
  publication-title: Pain
  doi: 10.1097/j.pain.0000000000001986
– volume: 9
  start-page: 1
  issue: 1
  year: 2019
  ident: 10.1016/j.npep.2024.102479_bb0040
  article-title: Perineural invasion of cancer: a complex crosstalk between cells and molecules in the perineural niche
  publication-title: Am. J. Cancer Res.
– volume: 295
  start-page: 2495
  issue: 8
  year: 2020
  ident: 10.1016/j.npep.2024.102479_bb0090
  article-title: Cell adhesion in cancer: beyond the migration of single cells
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.REV119.007759
– volume: 20
  start-page: 328
  year: 2020
  ident: 10.1016/j.npep.2024.102479_bb0105
  article-title: EO771, the first luminal B mammary cancer cell line from C57BL/6 mice
  publication-title: Cancer Cell Int.
  doi: 10.1186/s12935-020-01418-1
– volume: 8
  start-page: 373
  issue: 4
  year: 2015
  ident: 10.1016/j.npep.2024.102479_bb0225
  article-title: Nuclear p120-catenin regulates the anoikis resistance of mouse lobular breast cancer cells through Kaiso-dependent Wnt11 expression
  publication-title: Dis. Model. Mech.
– volume: 45
  start-page: 1658
  issue: 4
  year: 2014
  ident: 10.1016/j.npep.2024.102479_bb0140
  article-title: The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer
  publication-title: Int. J. Oncol.
  doi: 10.3892/ijo.2014.2565
– volume: 34
  start-page: 215
  issue: 1
  year: 2020
  ident: 10.1016/j.npep.2024.102479_bb0230
  article-title: Involvement of the substance P/neurokinin-1 receptor system in oral pain and inflammation
  publication-title: J. Biol. Regul. Homeost. Agents
– volume: 23
  start-page: 8479
  issue: 15
  year: 2022
  ident: 10.1016/j.npep.2024.102479_bb0150
  article-title: Targeting tumor acidosis and regulatory T cells unmasks anti-metastatic potential of local tumor ablation in triple-negative breast cancer
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms23158479
– volume: 20
  start-page: 2321
  issue: 9
  year: 2014
  ident: 10.1016/j.npep.2024.102479_bb0120
  article-title: Involvement of substance P and the NK-1 receptor in pancreatic cancer
  publication-title: World J. Gastroenterol.
  doi: 10.3748/wjg.v20.i9.2321
– volume: 11
  start-page: 50
  issue: 1
  year: 2019
  ident: 10.1016/j.npep.2024.102479_bb0145
  article-title: Neurokinin-1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: a case report
  publication-title: Mol. Clin. Oncol.
– start-page: 571
  issue: 8
  year: 2020
  ident: 10.1016/j.npep.2024.102479_bb0085
  article-title: Peptide-drug conjugates and their targets in advanced cancer therapies
  publication-title: Front. Chem.
  doi: 10.3389/fchem.2020.00571
– volume: 2015
  year: 2015
  ident: 10.1016/j.npep.2024.102479_bb0065
  article-title: Biological and pharmacological aspects of the NK1-receptor
  publication-title: Biomed. Res. Int.
  doi: 10.1155/2015/495704
– volume: 94
  start-page: 265
  issue: 1
  year: 2014
  ident: 10.1016/j.npep.2024.102479_bb0200
  article-title: Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease
  publication-title: Physiol. Rev.
  doi: 10.1152/physrev.00031.2013
– volume: 375
  start-page: 227
  issue: 1
  year: 2019
  ident: 10.1016/j.npep.2024.102479_bb0255
  article-title: Substance P and pain chronicity
  publication-title: Cell Tissue Res.
  doi: 10.1007/s00441-018-2922-y
– volume: 337
  start-page: 226
  issue: 1
  year: 2011
  ident: 10.1016/j.npep.2024.102479_bb0210
  article-title: Involvement of substance P in peripheral neuropathy induced by paclitaxel but not oxaliplatin
  publication-title: J. Pharmacol. Exp. Ther.
  doi: 10.1124/jpet.110.175976
– volume: 75
  start-page: 1777
  issue: 9
  year: 2015
  ident: 10.1016/j.npep.2024.102479_bb0095
  article-title: Nerve-cancer cell cross-talk: a novel promoter of tumor progression
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-14-3180
– volume: 16
  start-page: 1083
  issue: 10
  year: 2005
  ident: 10.1016/j.npep.2024.102479_bb0035
  article-title: Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231
  publication-title: Anti-Cancer Drugs
  doi: 10.1097/00001813-200511000-00007
– volume: 633
  start-page: 207
  issue: 8028
  year: 2024
  ident: 10.1016/j.npep.2024.102479_bb0165
  article-title: Neuronal substance P drives metastasis through an extracellular RNA-TLR7 axis
  publication-title: Nature
  doi: 10.1038/s41586-024-07767-5
– volume: 15
  year: 2019
  ident: 10.1016/j.npep.2024.102479_bb0075
  article-title: Tachykinins modulate nociceptive responsiveness and sensitization: in vivo electrical characterization of primary sensory neurons in tachykinin knockout (Tac1 KO) mice
  publication-title: Mol. Pain
  doi: 10.1177/1744806919845750
SSID ssj0004288
Score 2.4043052
Snippet Several data indicate that Substance P (SP) neurokinin type 1 receptor (NK1R) is at the center of the interaction between cancer cells and peripheral sensory...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 102479
SubjectTerms Aprepitant
Breast cancer
Microtumors
Neuropeptides
NK1R
Substance P
Title NK1 receptor blockade disrupts microtumor growth and aggregation in a three-dimensional murine breast cancer model
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0143417924000787
https://dx.doi.org/10.1016/j.npep.2024.102479
https://www.ncbi.nlm.nih.gov/pubmed/39591909
https://www.proquest.com/docview/3133414509
Volume 109
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELam7WG8ILbxo8AmT0K8INM0dpz6sao2FSr6gJjYm-XYl9KhZlGbPvDC386dkwxNGiDxFCmOFcff-XznfHfH2Bso0e8xSSJC6XNB-UlE4Q2IxCfaG10mWQwf-7TQsyv18Tq73mPTPhaGaJWd7m91etTW3Z1hN5vDerUaEi1JUv0sYkHiRkcR5ZS9DmX6_c_fNA80r8ctjVEKeroLnGk5XlUNlLMyVZTBQBGd6-HN6U_GZ9yELp-wx531yCftAI_YHlTH7GRSoee8_sHf8sjnjAflx-xw2tdyO2GbxXzE8TuhRhebF7iBfXcBeFhtN7u62fI10fKa3Robl-iXN9-4qwJ3S3TGlxE6vqq44w0CDyJQQYA2mQdf02E98IKo7Q33JEIbHqvrPGVXlxdfpjPRVVsQXmbjRui8kAZweZZodeggfRESiVAmTpvgx9Lh2s0ofU0-CoigygFbIXc4duOSrJDP2H51W8ELxkEVOvgsh5BLlabBlOi3gDZOg1FpaQbsXT_Ntm6TatiebXZjCRRLoNgWlAGTPRK2DxdFBWdR5_-1V3bX655A_bPfeQ-2RZDo94mr4Ha3tRLdeTVSaGEN2PNWCu5GL01m0LQyL__zra_Yo5QKC8eznddsv9ns4BStnaY4i-J8xg4mH-azBV3nn7_OfwHRqABb
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCa69NBdhrXdI3t0GjDsMghxLFmujkGwIl3anFqgN0GW5Cwd4hqJc9i_HynbHQZsK9CrbcKyPooi5Y8kwKdQYtyjk4T70uWc6pPwwunAE5cop1WZZDF97HKhZtfy2012swfTPheGaJWd7W9terTW3ZVRN5ujerUaES1JUP8sYkHiRpc_gX2qTiUHsD85n88Wv9Mj09h-kp7nJNDlzrQ0r6oOVLYylVTEQBKj6-_707_8z7gPnT2HZ50DySbtGA9hL1RHcDypMHhe_2SfWaR0xrPyIziY9u3cjmGzmI8ZfmqoMcpmBe5hP6wPzK-2m13dbNmamHnNbo03lxiaN9-ZrTyzS4zHlxE9tqqYZQ1iH7inngBtPQ-2pvP6wApitzfMkRZtWGyw8wKuz75eTWe8a7jAnchOG67yQuiAK7REx0N54QqfCEQzsUp7dyosLt-MKtjkY48gyjzg3ZBbHLu2SVaIlzCo7qrwGliQhfIuy4PPhUxTr0sMXYLSVgUt01IP4Us_zaZu62qYnnB2awgUQ6CYFpQhiB4J02eMoo0zaPb_K5XdS_2hUw_KfezBNggS_UGxVbjbbY3AiF6OJTpZQ3jVasH96IXONHpX-s0j3_oBDmZXlxfm4nwxfwtPU-ozHI963sGg2ezCe3R-muKkU-5fi_MBaQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=NK1+receptor+blockade+disrupts+microtumor+growth+and+aggregation+in+a+three-dimensional+murine+breast+cancer+model&rft.jtitle=Neuropeptides+%28Edinburgh%29&rft.au=Gutierrez%2C+Silvia&rft.au=Boada%2C+M+Danilo&rft.date=2025-01-01&rft.eissn=1532-2785&rft.volume=109&rft.spage=102479&rft_id=info:doi/10.1016%2Fj.npep.2024.102479&rft_id=info%3Apmid%2F39591909&rft.externalDocID=39591909
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0143-4179&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0143-4179&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0143-4179&client=summon